LeonaBio, Inc. Net Change in Cash
LeonaBio, Inc. (LONA) reported Net Change in Cash of -$36.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-14
- LeonaBio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$36.44M.
- LeonaBio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$22.02M.
- LeonaBio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$12.76M, a 235.39% decline year-over-year.
- LeonaBio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $9.43M, a 25.96% increase year-over-year.
- LeonaBio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $20.84M.
- LeonaBio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$42.15M.
- LeonaBio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$5.17M.
- LeonaBio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$14.15M, a 128.35% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$36.95M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | -$36.44M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $20.84M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | -$27.56M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$28.55M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$22.02M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$42.15M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | -$13.36M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$8.38M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$12.76M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | -$5.17M 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $14.58M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $17.87M 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | $9.43M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$14.15M 10-K · filed 2024-02-22 | |||
| 2022-09-30 | -$23.28M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$15.27M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $7.48M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $49.91M 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $46.70M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $71.08M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $67.20M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $58.57M 10-K · filed 2022-03-28 | |||
| 2020-09-30 | $163.67M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $83.11M 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | $666.00K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | -$1.26M 10-K · filed 2021-03-25 | |||
| 2019-09-30 | -$1.04M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |